PDCD1 and neoplasm: A novel ‘plug-and-play’ approach involving the modification of programmed death protein-1 (PD-1) on the outer membrane of BEVs has been developed to enhance PD-L1 binding to tumor cells while safeguarding T cells from the PD-1/PD-L1 immunosuppressive pathway (124).